Creative Biolabs is an undisputed global leader providing customized in vitro diagnostic (IVD) antibody discovery and development services targeting various biomarkers for a wide variety of diseases. Especially, we offer high-quality IVD antibody discovery services against UH-RA.1 marker using our advanced technologies.

Identification of UH-RA Peptides as Biomarkers for RA

Recent progress in biomarker discovery for RA diagnostics makes contribution to the presence of previously identified autoantibodies to novel Hasselt University (UH) peptides in early and seronegative RA. As is reported in paper, researchers from Europe have been studying four novel candidate biomarkers (UH-RA.1, UH-RA.9, UH-RA.14 and UH-RA.21) that binding to one biomarker panel to identify early RA. About 300 people with Rheumatoid Disease (PRD) participate in the study, including some patients identified as otherwise seronegative. The results suggest that the UH peptides biomarkers enable the identification of 26% of the RF-negative ACCP-negative subpopulation, thereby about 7% more PRD could be identified by adding this biomarker panel to the usual Rf and anti-CCP. Within the patient group, the positive test confirms the peptide’s ability to indicate reactivity in early disease. Early disease markers are of the utmost importance when aiming at preventing joint damage and disability.

UH-RA.1 Marker-Creative Biolabs.

Function of Biomarkers in Rheumatoid Arthritis

  • Diagnosis of disease;
  • Prediction and assessment of prognosis: a. joint destruction; b. extra-articular diseases; c. quality of life;
  • Prediction and assessment of response to therapy;
  • Prediction and assessment of drug toxicity.

IVD Antibody Development Services for UH-RA.1 Marker

UH-RA.1 is promising in the test with the highest prevalence and their presence was particularly observed in early disease. Up to one-third of early RA patients from the UH cohort tested positive for at least one of these autoantibodies. Their presence in early disease was further validated in 600 early RA patients from the cohort. Related researches results indicate a role for UH-RA.1 antibody testing to increase the diagnostic window and eventually close the serological gap. Exploration of the prognostic potential of anti-UH-RA antibodies pointed towards a better outcome linked to anti-UH-RA.1 antibodies.

In order to improve the value of these antibody-based diagnostic tools and help clinicians in the diagnosis, prognosis, and staging of rheumatoid arthritis, Creative Biolabs is providing IVD antibody development services to produce high-quality antibodies for diagnostic use. Moreover, we can develop high-quality antibody pairs targeting UH-RA.1 using our advanced antibody development technologies, such as hybridoma technology. Furthermore, we also offer IVD kit development from scratch or using available antibodies provided by the client.

In addition to rheumatoid arthritis, areas of research covered here include cancer, apoptosis, neurobiology, autoimmune diseases, cardiovascular diseases, infectious diseases, and so on. Creative Biolabs will choose the most suitable approach to fulfill the client's demand for IVD antibodies, according to customer's detailed requirements. Please feel free to contact us for more information and a detailed quote.

Online Inquiry

*E-mail Address:
*Service & Products Interested:
Project Description:
*Verification Code:
Please input "biolabs"(case insensitive) as verification code.

Contact Us

45-1 Ramsey Road, Shirley, NY 11967, USA
Tel: 1-631-381-2994
Fax: 1-631-207-8356

Follow us on:
Copyright ©2011 - 2019 Creative Biolabs.